Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
GBT-440 is a modulator of sickle hemoglobin (HbS) that binds covalently to the N-terminal valine of the α chain of HbS.1 In vitro, GBT-440 increases HbS affinity for oxygen (EC50s = 8.2 and 415 μM for purified HbS and whole blood from sickle cell anemia patients, respectively) and delays oxygen release from and polymerization of HbS in a concentration-dependent manner. GBT-440 (100-150 mg/kg) increases red blood cell half-life and reduces sickling ex vivo in whole blood isolated from a murine model of sickle cell anemia. It also reduces ex vivo sickling of sickle cell trait red blood cells under conditions of hypoxia, acidosis, and dehydration.2
WARNING This product is not for human or veterinary use.
1. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-
2. GBT440 inhibits sickling of sickle cell trait blood under in vitro conditions mimicking strenuous exercise. Hematol. Rep. 8(3), 6637 (2016).